Login to Your Account


Growth strategy: Biomarin mulls best dose for dwarfism therapy heading into phase III

By Randy Osborne
Staff Writer

Thursday, June 18, 2015

Biomarin Pharmaceutical Inc. is considering the design to be sought for the pivotal phase III trial with BMN 111 (vosoritide), an analog of C-type natriuretic peptide (CNP), in children with achondroplasia, thanks to strong results with the highest of three doses – 15 µg/kg/daily – in a phase II experiment that enrolled 26 children with a mean age of 7.8 years.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription